|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||5 to 6 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||628.810 g/mol g·mol−1|
|3D model (JSmol)|
It was patented in 1995 and approved for medical use in 2000.
Side effects, interactions, and contraindications have only been evaluated in the drug combination lopinavir/ritonavir.
Lopinavir is highly bound to plasma proteins (98–99%).
Reports are contradictory regarding lopinavir penetration into the cerebrospinal fluid (CSF). Anecdotal reports state that lopinavir cannot be detected in the CSF; however, a study of paired CSF-plasma samples from 26 patients receiving lopinavir/ritonavir found lopinavir CSF levels above the IC50 in 77% of samples.
A 2014 study indicates that lopinavir is effective against the human papilloma virus (HPV). The study used the equivalent of one tablet twice a day applied topically to the cervices of women with high-grade and low-grade precancerous conditions. After three months of treatment, 82.6% of the women who had high-grade disease had normal cervical conditions, confirmed by smears and biopsies.
- "FDA Approved Drug Products: Kaletra". Retrieved 30 April 2004.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 510. ISBN 9783527607495.
- KALETRA (lopinavir/ritonavir) capsules; (lopinavir/ritonavir) oral solution. Prescribing information. April 2009
- Capparelli E, Holland D, Okamoto C, et al. (2005). "Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV". AIDS. 19 (9).
- HIV drug used to reverse effects of virus that causes cervical cancer University of Manchester, 17 February 2014.